Dicerna Pharmaceuticals Raises Additional $4M in Series B, Bringing Total to $29M

SR One, the venture capital arm of GlaxoSmithKline, participated in the financing as a new investor, joining existing investors Oxford Bioscience Partners, Skyline Ventures, Abingworth, and Domain Associates.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories